Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02045277 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

A Phase 2 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 2
Development phase
212
Enrollment target

NCT02045277 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 212 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02045277, a Phase 2 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 2
Development phase
212 participants
Enrollment target

Study Summary

The objective of the study is to evaluate the safety and efficacy of a topical lotion

Interventions

  • DRUG IDP-118 Lotion
  • DRUG IDP-118 Vehicle Lotion
  • DRUG IDP-118 Monad HP Lotion
  • DRUG IDP-118 Monad Taz Lotion

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2014-02
Est. Completion 2014-11
Phase Phase 2

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT02045277

The ClinicalTrials.gov registry entry for NCT02045277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which IDP-118 Lotion is the first listed.

NCT02045277 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02045277 about?

NCT02045277 is a clinical study titled "Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis". The objective of the study is to evaluate the safety and efficacy of a topical lotion

What is the current status of trial NCT02045277?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2014-02. Estimated completion is 2014-11.

What interventions are being tested in trial NCT02045277?

The interventions under investigation include: IDP-118 Lotion (DRUG), IDP-118 Vehicle Lotion (DRUG), IDP-118 Monad HP Lotion (DRUG), IDP-118 Monad Taz Lotion (DRUG).

Who is sponsoring clinical trial NCT02045277?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.